Reshma Kewalramani, Vertex CEO
July 11, 2022 10:55 AM EDTUpdated 11:16 AM
Deals
Cell/Gene Tx

Ver­tex nabs Vi­a­Cyte's ri­val di­a­betes stem cell treat­ment, ac­quir­ing the biotech for $320M in cash

Max Gelman

Senior Editor

Less than a week af­ter the FDA lift­ed a hold on Ver­tex’s stem cell ther­a­py for type 1 di­a­betes, the Boston com­pa­ny is buy­ing out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ei­sai takes over de­vel­op­ment of ADC af­ter Bris­tol My­ers ends $650M col­lab­o­ra­tion

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

Arti­va re­files for IPO three years af­ter orig­i­nal plans in a vast­ly dif­fer­ent en­vi­ron­ment

Di­anthus teas­es pre­clin­i­cal da­ta for au­toim­mune drug as its starts clin­i­cal tri­als

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

EMA's CHMP rec­om­mends 10 new drugs as Pierre Fab­re over­ac­tive blad­der med wins ap­proval

A service from the Financial Times